Biosimilars Bulletin | March 2023

To our biosimilars advocates,

As you will see below, we have made some changes to our monthly bulletin. Our goal is to offer up timely, relevant analyses and updates in a digestible, streamlined format, and we hope this newsletter accomplishes that. You’ll find a recap of the top biosimilars stories from the previous month, along with brief commentary on upcoming opportunities or challenges for biosimilars. So, without further ado, here’s a look at what happened last month.

Biosimilar versions of Humira (adalimumab) continued to generate attention, with the news that PBMs are covering the higher-cost biosimilar but excluding the lower-list price version. This continues to shine light on PBM preferences for products with high rebates. As we’ve previously noted, it will take some time for adoption and savings from biosimilar adalimumab to kick in.

Learn What Experts Are Saying

As biosimilars advocates, we must continue raising public awareness of and support for biosimilars.

Separately, we were pleased to see the FDA introduce a helpful fact sheet and materials from a workshop that help communicate the benefits of biosimilars for patients (check out our Patient Resource Center for more helpful resources), building public momentum behind increased access.

This month, we were also proud to serve as partners for the Festival of Biologics, an annual scientific conference featuring extensive discussion of challenges and opportunities for the development and adoption of biosimilars. I was encouraged by the shared urgency among attendees of the need to increase education and work with policymakers to bring biosimilars to market more quickly and encourage more rapid adoption of biosimilars. Looking forward, we are at a critical point in the evolution of the biosimilars market.

And the increasing attention on biosimilars presents an opportunity to highlight the way that biosimilars expand patient access to care and advance solutions to increase biosimilar competition and adoption. We appreciate your support of this goal. Be sure to check your inbox for our next newsletter, and check out our website for regular updates, blogs, resources and advocacy tools.

–Craig

Encourage the adoption of biosimilars in the U.S. by forwarding this newsletter to a colleague or friend. They can subscribe here.

Want to hear directly from Executive Director Craig Burton?

Follow him on LinkedIn

Interested in joining the Biosimilars Council?

Contact Jewel Smith (jewel.smith@accessiblemeds.org) for more information.